Form 4: Karyopharm Therapeutics CEO Sells Shares to Cover Tax Obligations

Karyopharm Therapeutics CEO Richard Paulson sold 3,620 shares of common stock at $0.81 per share to cover tax obligations related to vesting restricted stock units.

Summary

• Richard Paulson, the President and CEO of Karyopharm Therapeutics, sold 3,620 shares of common stock on December 4, 2024.
• The sale was executed at a price of $0.81 per share.
• This transaction was not a discretionary trade but was part of a pre-arranged plan to cover withholding tax liabilities.
• The sale was triggered by the vesting of restricted stock units.
• Following the transaction, Paulson directly owns 1,128,312 shares of Karyopharm Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar transactions by executives at other firms.
• The sale of 3,620 shares is relatively small compared to the total holdings of 1,128,312 shares, suggesting it is a routine tax-related transaction rather than a significant change in the executive's investment position.

Stakeholder Impact

• The sale is unlikely to have a significant impact on shareholders as it is a small transaction related to tax obligations.

Key Dates

Keywords

Karyopharm Therapeutics, Richard Paulson, stock sale, insider trading, SEC Form 4, restricted stock units, tax obligations